Recently, ASK1 has attracted much attention because of its pathogenic role in non-alcoholic steatohepatitis (NASH), which led to the ASK1 inhibitor selonsertib entering human clinical trials [49,50]. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.